Rainbow Children's Medicare Board Approves Final Dividend of ₹3.5/Share, Reappoints CMD
Rainbow Children's Medicare Board approved audited financial results for FY26. A final dividend of ₹3.5 per share was recommended, subject to shareholder approval at the AGM on July 29, 2026. Record date set for July 21, 2026. Dr. Ramesh Kancharla re-appointed CMD for five years.
The dividend recommendation and re-appointment of CMD are significant for the company's governance and shareholder value, but do not immediately alter the business operations.
The announcement includes a positive development of a recommended dividend and re-appointment of key management personnel, indicating stability and shareholder returns.
Rainbow Children's Medicare Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with an unmodified opinion from statutory auditors S.R. Batliboi & Associates LLP.
The Board recommended a final dividend of ₹3.5 per equity share (35% on a face value of ₹10), subject to shareholder approval at the upcoming 28th Annual General Meeting (AGM). The dividend will be dispatched/credited within 30 days of the AGM.
The 28th AGM is scheduled to be held on Wednesday, July 29, 2026, through Video Conferencing/Other Audio-Visual Means (VC/OVAM). Tuesday, July 21, 2026, has been fixed as the Record Date for the dividend payment and the AGM.
Furthermore, the Board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director for a period of five years from August 11, 2026, to August 10, 2031. Dr. Dinesh Kumar Chirla was re-appointed as Whole Time Director for a similar five-year term. Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms of five years each, commencing from October 22, 2026, and September 16, 2026, respectively. The re-appointments are subject to shareholder approval at the AGM.
Additionally, M/s. Lavanya & Associates LLP was re-appointed as the Cost Auditors for the Financial Year 2026-27. The Board Meeting commenced at 4:45 PM and concluded at 6:30 PM.
What to do with a filing like this
Rainbow Childrens Medicare Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rainbow Childrens Medicare Limited. Read the original for the full detail.